Zegerid deal solidifies
This article was originally published in The Tan Sheet
Executive Summary
A Santarus license agreement with Schering-Plough for OTC commercialization rights to its immediate-release omeprazole product Zegerid is now effective, as the waiting period required under antitrust law has expired, the firm announces Nov. 21. Santarus expects the proton pump inhibitor's quick action to give it a competitive advantage over P&G's Prilsoec OTC if S-P can gain approval for an Rx-to-OTC switch. The agreement includes a $15 mil. upfront license fee and up to $65 mil. in additional milestone payments (1"The Tan Sheet" Oct. 23, 2006, p. 3)...